Evaluating the Primary Prevention of Ischemic Stroke of Oral Antithrombotic Therapy in Head and Neck Cancer Patients with Radiation Therapy

Table 2

Incidence of study outcomes in head and neck cancer patients with radiation therapy between oral antithrombotic therapy users and nonusers.

Follow-up method	Outcome	Nonuser			User
		Number of events	Total person-years	Incidence rate^†	Number of events	Total person-years	Incidence rate^†
Study population: nonuser (); user ()
Method I	Ischemic stroke or TIA	600	107648.01	5.57	21	2034.16	10.32
	Death	1220	108714.85	11.22	39	2087.92	18.68
	Major bleeding	1730	106366.72	16.26	43	2037.69	21.10
Method II	Ischemic stroke or TIA	613	109023.26	5.62	2	318.45	6.28
	Death	1237	110096.69	11.24	20	318.62	62.77
	Major bleeding	1762	107720.68	16.36	14	314.46	44.52
Study population after 1-to-1 propensity score matching: nonuser (); user ()
Method I	Ischemic stroke or TIA	12	1995.20	6.01	21	2034.16	10.32
	Death	26	2007.16	12.95	39	2087.92	18.68
	Major bleeding	46	1928.04	23.86	43	2037.69	21.10
Method II	Ischemic stroke or TIA	25	3370.45	7.42	2	318.45	6.28
	Death	43	3389.00	12.69	20	318.62	62.77
	Major bleeding	78	3281.99	23.77	14	314.46	44.52

TIA, transient ischemic attack.
of incidence rate: 1,000 person-years.